Intellia Therapeutics News Headlines (NASDAQ:NTLA)

$14.35
-0.06 (-0.42 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$14.16
Now: $14.35
$14.62
50-Day Range
$12.9451
MA: $15.68
$17.72
52-Week Range
$11.03
Now: $14.35
$31.51
Volume342,318 shs
Average Volume409,124 shs
Market Capitalization$701.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71

Headlines

Intellia Therapeutics (NASDAQ NTLA) News Headlines

Source:
DateHeadline
Introducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Slid 52% In The Last YearIntroducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Slid 52% In The Last Year
finance.yahoo.com - September 13 at 6:55 AM
Intellia Therapeutics Inc (NASDAQ:NTLA) Given Average Rating of "Hold" by BrokeragesIntellia Therapeutics Inc (NASDAQ:NTLA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 4 at 6:28 AM
$9.14 Million in Sales Expected for Intellia Therapeutics Inc (NASDAQ:NTLA) This Quarter$9.14 Million in Sales Expected for Intellia Therapeutics Inc (NASDAQ:NTLA) This Quarter
www.americanbankingnews.com - September 1 at 1:38 AM
Zacks: Brokerages Expect Intellia Therapeutics Inc (NASDAQ:NTLA) to Post -$0.61 EPSZacks: Brokerages Expect Intellia Therapeutics Inc (NASDAQ:NTLA) to Post -$0.61 EPS
www.americanbankingnews.com - August 30 at 8:15 PM
Short Interest in Intellia Therapeutics Inc (NASDAQ:NTLA) Declines By 9.4%Short Interest in Intellia Therapeutics Inc (NASDAQ:NTLA) Declines By 9.4%
www.americanbankingnews.com - August 28 at 7:56 PM
Intellia files $300M mixed shelf registrationIntellia files $300M mixed shelf registration
seekingalpha.com - August 23 at 6:37 PM
Edited Transcript of NTLA earnings conference call or presentation 1-Aug-19 12:00pm GMTEdited Transcript of NTLA earnings conference call or presentation 1-Aug-19 12:00pm GMT
finance.yahoo.com - August 6 at 8:35 AM
Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call TranscriptIntellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript
finance.yahoo.com - August 1 at 7:05 PM
 Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update
finance.yahoo.com - August 1 at 8:59 AM
Intellia Therapeutics Q2 2019 Earnings PreviewIntellia Therapeutics Q2 2019 Earnings Preview
seekingalpha.com - July 31 at 6:58 PM
Intellia Therapeutics to Present at August Healthcare Investor ConferenceIntellia Therapeutics to Present at August Healthcare Investor Conference
finance.yahoo.com - July 30 at 8:26 AM
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company UpdateIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
www.nasdaq.com - July 25 at 9:26 AM
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company UpdateIntellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2019 Earnings and Company Update
finance.yahoo.com - July 25 at 9:26 AM
Baird: Preclinical Data Inspires Early Optimism In Lead Intellia Therapeutics AssetBaird: Preclinical Data Inspires 'Early Optimism' In Lead Intellia Therapeutics Asset
finance.yahoo.com - July 9 at 5:47 PM
Intellia +1% after Baird start at OutperformIntellia +1% after Baird start at Outperform
seekingalpha.com - July 9 at 9:27 AM
Here is What Hedge Funds Think About Intellia Therapeutics, Inc. (NTLA)Here is What Hedge Funds Think About Intellia Therapeutics, Inc. (NTLA)
finance.yahoo.com - June 30 at 9:09 AM
Better Buy: Cara Therapeutics vs. Intellia TherapeuticsBetter Buy: Cara Therapeutics vs. Intellia Therapeutics
www.fool.com - June 16 at 9:34 AM
Glaxo Inks Genome Research Deal With University of CaliforniaGlaxo Inks Genome Research Deal With University of California
finance.yahoo.com - June 14 at 9:38 AM
How Many Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Did Insiders Buy, In The Last Year?How Many Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Did Insiders Buy, In The Last Year?
finance.yahoo.com - June 10 at 10:04 AM
Heres Why CRISPR Gene Editing Stocks Lost as Much as 17% in MayHere's Why CRISPR Gene Editing Stocks Lost as Much as 17% in May
www.nasdaq.com - June 5 at 9:11 AM
Intellia Therapeutics to Participate at June Healthcare Investor ConferencesIntellia Therapeutics to Participate at June Healthcare Investor Conferences
finance.yahoo.com - May 30 at 5:52 PM
Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific OfficerIntellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
finance.yahoo.com - May 28 at 9:18 AM
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy?Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy?
finance.yahoo.com - May 10 at 9:24 AM
Edited Transcript of NTLA earnings conference call or presentation 2-May-19 12:00pm GMTEdited Transcript of NTLA earnings conference call or presentation 2-May-19 12:00pm GMT
finance.yahoo.com - May 3 at 6:29 PM
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2019 Results - Earnings Call TranscriptIntellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 6:56 PM
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue EstimatesIntellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 2 at 6:56 PM
Intellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call TranscriptIntellia Therapeutics, Inc. (NTLA) Q1 2019 Earnings Call Transcript
finance.yahoo.com - May 2 at 6:56 PM
Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company UpdateIntellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
finance.yahoo.com - May 2 at 9:26 AM
Intellia Therapeutics Q1 2019 Earnings PreviewIntellia Therapeutics Q1 2019 Earnings Preview
seekingalpha.com - May 1 at 6:34 PM
Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell TherapyIntellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
finance.yahoo.com - April 29 at 9:13 AM
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company UpdateIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
finance.yahoo.com - April 25 at 9:17 AM
Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell TherapyIntellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
finance.yahoo.com - April 15 at 6:29 PM
Intellia Therapeutics IncIntellia Therapeutics Inc
www.bloomberg.com - March 19 at 9:39 AM
Some Intellia Therapeutics (NASDAQ:NTLA) Shareholders Have Copped A Big 50% Share Price DropSome Intellia Therapeutics (NASDAQ:NTLA) Shareholders Have Copped A Big 50% Share Price Drop
finance.yahoo.com - March 12 at 10:17 AM
5 Top Gene-Editing Stocks for 2019 - Motley Fool5 Top Gene-Editing Stocks for 2019 - Motley Fool
www.fool.com - March 8 at 9:43 AM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial ResultsIntellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
www.globenewswire.com - February 27 at 9:24 AM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial ResultsIntellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
finance.yahoo.com - February 27 at 9:24 AM
Moderna Proving It Could Upend Much Of The Biotech IndustryModerna Proving It Could Upend Much Of The Biotech Industry
seekingalpha.com - February 26 at 5:53 PM
Better Buy: Editas Medicine vs. Intellia Therapeutics - The Motley FoolBetter Buy: Editas Medicine vs. Intellia Therapeutics - The Motley Fool
www.fool.com - February 24 at 10:34 PM
BTIG likes CRISPR/Cas9 gene editors in premarket analyst actionBTIG likes CRISPR/Cas9 gene editors in premarket analyst action
seekingalpha.com - February 8 at 9:25 AM
Crispr Therapeutics: Second-Half 2018 Review - Where Does It Go From Here?Crispr Therapeutics: Second-Half 2018 Review - Where Does It Go From Here?
seekingalpha.com - January 25 at 9:16 AM
Intellia Therapeutics Names Fred Cohen, M.D., to Board of DirectorsIntellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
finance.yahoo.com - January 24 at 9:29 AM
Here's Why Intellia Therapeutics Stock Lost 23.8% in DecemberHere's Why Intellia Therapeutics Stock Lost 23.8% in December
finance.yahoo.com - January 11 at 5:46 PM
Heres Why Intellia Therapeutics Stock Lost 23.8% in DecemberHere's Why Intellia Therapeutics Stock Lost 23.8% in December
www.fool.com - January 11 at 9:38 AM
Intellia Therapeutics Inc.Intellia Therapeutics Inc.
www.barrons.com - December 21 at 4:50 PM
Chinas Gene-Editing Scientists Still Aiming for Crispr Supremacy - BloombergChina's Gene-Editing Scientists Still Aiming for Crispr Supremacy - Bloomberg
www.bloomberg.com - December 13 at 5:00 PM
Intellia nabs $10M from Novartis on expanded partnershipIntellia nabs $10M from Novartis on expanded partnership
seekingalpha.com - December 6 at 4:47 PM
Long-Term Outlook For IntelliaLong-Term Outlook For Intellia
seekingalpha.com - December 6 at 4:47 PM
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell PopulationIntellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
finance.yahoo.com - December 6 at 9:11 AM
Landmark Gene-Editing Study Advances After China Crispr Clamor - BloombergLandmark Gene-Editing Study Advances After China Crispr Clamor - Bloomberg
www.bloomberg.com - December 1 at 4:27 PM
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel